Heinrichs, RW, Zakzanis, KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology
1998; 12: 426–45.
Saykin, AJ, Gur, RC, Gur, RE, Mozley, PD, Mozley, LH, Resnick, SM, et al. Neuropsychological function in schizophrenia. Selective impairment in memory and learning. Arch Gen Psychiatry
1991; 48: 618–24.
Cuesta, MJ, Peralta, V, Caro, F, de Leon, J. Schizophrenic syndrome and Wisconsin Card Sorting Test dimensions. Psychiatry Res
1995; 58: 45–51.
Heaton, RK, Gladsjo, JA, Palmer, BW, Kuck, J, Marcotte, TD, Jeste, DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry
2001; 58: 24–32.
Kraus, MS, Keefe, RSE. Cognition as an outcome measure in schizophrenia. Br J Psychiatry
2007; 191 (suppl 50): s46–51.
Green, MF. What are the functional consequences of neurocognitive deficits in schizophrenia?
Am J Psychiatry
1996; 153: 321–30.
Green, MF. Cognition, drug treatment, and functional outcome in schizophrenia: a tale of two transitions. Am J Psychiatry
2007; 164: 992–4.
Cuesta, MJ, Peralta, V, Zarzuela, A. Illness duration and neuropsychological impairments in schizophrenia. Schizophr Res
1998; 33: 141–50.
Heaton, RK, Crowley, TJ. Effects of psychiatry disorders and their somatic treatments on neuropsychological test results. In Handbook of Clinical Neuropsychology (eds Filskov, SB, Boll, TJ): 481–525. Wiley, 1981.
Medalia, A, Gold, J, Merriam, A. The effect of neuroleptics on neuropsychological test results of schizophrenics. Arch Clin Neuropsychol.
1988; 3: 249–71.
Spohn, HE, Strauss, ME. Relation of neuroleptic and anticholinergic medication to cognitive fuctions in schizophrenia. J Abnorm Psychol
1989; 98: 367–80.
Cassens, G, Inglis, AK, Appelbaum, PS, Gutheil, TG. Neuroleptics: effects on neuropsychological function in chronic schizophrenic patients. Schizophr Bull
1990; 16: 477–99.
King, DJ. The effect of neuroleptics on cognitive and psychomotor function. Br J Psychiatry
1990; 157: 799–811.
Weickert, TW, Goldberg, TE. First- and second-generation antipsychotic medication and cognitive processing in schizophrenia. Curr Psychiatry Rep
2005; 7: 304–10.
Mishara, AL, Goldberg, TE. A meta-analysis and critical review of the effects of conventional neuroleptic treatment on cognition in schizophrenia: opening a closed book. Biol Psychiatry
2004; 55: 1013–22.
Woodward, ND, Purdon, SE, Meltzer, HY, Zald, DH. A meta-analysis of cognitive change with haloperidol in clinical trials of atypical antipsychotics: dose effects and comparison to practice effects. Schizophr Res
2007; 89: 211–24.
Keefe, RS, Bilder, RM, Davis, SM, Harvey, PD, Palmer, BW, Gold, JM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. Arch Gen Psychiatry
2007; 64: 633–47.
Sharma, T. Cognitive effects of conventional and atypical antipsychotics in schizophrenia. Br J Psychiatry
1999; 174 (suppl 38): s44–51.
Goldberg, TE, Goldman, RS, Burdick, KE, Malhotra, AK, Lencz, T, Patel, RC, et al. Cognitive improvement after treatment with second-generation antipsychotic medications in first-episode schizophrenia: is it a practice effect?
Arch Gen Psychiatry
2007; 64: 1115–22.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders (4th edn, text revision) (DSM–IV–TR). APA, 2000.
Andreasen, NC, Flaum, M, Arndt, S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry
1992; 49: 615–23.
Woods, SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry
2003; 64: 663–67.
Osterberg, L, Blaschke, T. Adherence to medication. N Engl J Med
2005; 353: 487–97.
Reitan, RM, Wolfson, D. The Halstead-Reitan Neuropsychological Test Battery: Theory and Clinical Interpretation. Neuropsychology Press, 1985.
Wechsler, DA. Standarized memory scale for clinical use. J Psychology
1945; 19: 87–95.
Spaulding, W, Garbin, CP, Dras, SR. Cognitive abnormalities in schizophrenic patients and schizotypal college students. J Nerv Ment Dis
1989; 177: 717–28.
Penn, DL, Van Der Does, W, Spaulding, W, Garbin, CP, Linszen, D, et al. Information processing and social cognitive problem solving in schizophrenia. J Nerv Ment Dis
1993; 181: 13–20.
Hair, JF, Black, B, Babin, B, Anderson, RE, Tatham, RL. Multivariate Data Analysis (6th edn). Pearson Prentice Hall, 2005.
Brown, L, Sherbenou, RJ, Johnsen, SK. TONI-2 Test de Inteligencia No Verbal. TEA Ediciones, 1995.
Jacobson, NS, Truax, P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol
1991; 59: 12–9.
Saykin, AJ, Shtasel, DL, Gur, RE, Kester, DB, Mozley, LH, Stafiniak, P, et al. Neuropsychological deficits in neuroleptic naive patients with first-episode schizophrenia. Arch Gen Psychiatry
1994; 51: 124–31.
Bilder, RM, Goldman, RS, Robinson, D, Reiter, G, Bell, L, Bates, JA, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry
2000; 157: 549–59.
Lee, SM, Chou, YH, Li, MH, Wan, FJ, Yen, MH. Effects of antipsychotics on cognitive performance in drug-naive schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry
2007; 31: 1101–7.
Townsend, LA, Norman, RM. Course of cognitive functioning in first episode schizophrenia spectrum disorders. Expert Rev Neurother
2004; 4: 61–8.
Mohamed, S, Paulsen, JS, O'Leary, D, Arndt, S, Andreasen, N. Generalized cognitive deficits in schizophrenia: a study of first-episode patients. Arch Gen Psychiatry
1999; 56: 749–54.
Riley, EM, McGovern, D, Mockler, D, Doku, VC, OCeallaigh, S, Fannon, DG, et al. Neuropsychological functioning in first-episode psychosis – evidence of specific deficits. Schizophr Res
2000; 43: 47–55.
Goldstein, G, Shemansky, WJ. Influences on cognitive heterogeneity in schizophrenia. Schizophr Res
1995; 18: 59–69.
González-Blanch, C, Alvarez-Jiménez, M, Rodríguez-Sánchez, JM, Pérez-Iglesias, R, Vázquez-Barquero, JL, Crespo-Facorro, B. Cognitive functioning in the early course of first-episode schizophrenia spectrum disorders: timing and patterns. Eur Arch Psychiatry Clin Neurosci
2006; 256: 364–71.
Peralta, V, Cuesta, MJ. A dimensional and categorical architecture for the classification of psychotic disorders. World Psychiatry
2007; 6: 36–7.
Reichenberg, A, Weiser, M, Rapp, MA, Rabinowitz, J, Caspi, A, Schmeidler, J, et al. Pre-morbid intra-individual variability in intellectual performance and risk for schizophrenia: a population-based study. Schizophr Res
2006; 85: 49–57.
Cannon, M, Caspi, A, Moffit, TE, Harrington, H, Taylor, A, Murray, RM, et al. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch Gen Psychiatry
2002; 59: 449–56.
Heaton, RK, Temkin, N, Dikmen, S, Avitable, N, Taylor, MJ, Marcotte, TD, et al. Detecting change: a comparison of three neuropsychological methods, using normal and clinical samples. Arch Clin Neuropsychol
2001; 16: 75–91.
Keefe, RS, Sweeney, JA, Gu, H, Hamer, RM, Perkins, DO, McEvoy, JP, et al. Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. Am J Psychiatry
2007; 164: 1061–71.
Cuesta, MJ, Peralta, V, Zarzuela, A. Effects of olanzapine and other antipsychotics on cognitive function in chronic schizophrenia: a longitudinal study. Schizophr Res
2001; 48: 17–28.
Lezak, MD. Neuropsychological Assessment (3rd edn). Oxford University Press, 1995.
Vickers, AJ. How many repeated measures in repeated measures designs? Statistical issues for comparative trials. BMC Med Res Methodol
2003; 3: 22.
Allison, DB, Allison, RL, Faith, MS, Paultre, F, Pi-Sunyer, FX. Power and money: designing statistically powerful studies while minimizing financial costs. Psychol Methods
1997; 2: 20–33.